FDA to ALS biotech Genervon: Show us the data
This article was originally published in Scrip
Executive Summary
The FDA on 17 April issued a rare statement calling for a tiny California biotech to release all the data from its recently completed trial of the company's experimental drug for amyotrophic lateral sclerosis (ALS), often called Lou Gehrig's disease, a progressive, invariably fatal neurodegenerative condition, which affects the nerve cells responsible for controlling voluntary muscles.